Updated:
NRX Pharmaceuticals
NRX Pharmaceuticals, led by Jonathan Javitt, is advancing a ketamine-based therapy for suicidal bipolar depression through late-stage FDA trials.
NRX Pharmaceuticals
NRX Pharmaceuticals was established by Dr. Jonathan Javitt, an academic and public-health veteran who previously founded several biotechnology firms including NeuroRx, which merged with a SPAC to form the current entity in May 2021. The company's wealth origin is venture-backed and publicly traded, not family money. Javitt also serves as an adjunct professor at Johns Hopkins School of Medicine, anchoring the firm in academic psychiatry rather than traditional biotech finance circles. NRX deploys capital toward central nervous system drug development, concentrating on bipolar depression with suicidality, post-traumatic stress disorder, and chronic pain. Its lead asset, NRX-101, combines D-cycloserine and lurasidone in an oral regimen and has received Qualified Infectious Disease Product and Fast Track designations from the FDA. The company also holds rights to NRX-100, an intravenous ketamine formulation. Deployment is structured entirely through internal clinical programs and a manufacturing supply-chain partnership with Nephron Pharmaceuticals, confirmed via an exclusive contract (per the firm, 2023). Operations target the United States regulatory market exclusively. The firm maintains roughly 20 professionals across clinical, regulatory, and commercial functions, headquartered in Radnor, Pennsylvania. Adjacent vehicles include the nonprofit Brain and Behavior Research Foundation, to which Javitt has longstanding ties, though no formal philanthropic vehicle sits within NRX's corporate structure. In July 2024, NRX announced that an independent Data Safety Monitoring Board recommended continuing its Phase 2b/3 trial of NRX-101 without modification, clearing a key clinical hurdle (per the firm, July 2024). NRX differs structurally from a conventional pharmaceutical asset manager in that it is a publicly traded, single-asset clinical-stage company — effectively a binary bet on one regulatory outcome. Its SPAC origin, through the Big Rock Partners acquisition vehicle, ties its capital formation to a mechanism now largely out of favor, marking its balance sheet as a legacy of the 2020–2021 biotech listing boom.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Radnor
Corporate office
Radnor, PA, United States
Principals
Jonathan Javitt
Chairman and Chief Scientist
Stephen Willard
Chief Executive Officer
Sector focus
Frequently asked questions
Who controls the clinical and regulatory strategy at NRX Pharmaceuticals?
Dr. Jonathan Javitt, the firm's founder, Chairman, and Chief Scientist, runs clinical and regulatory decisions. He has a public-health career spanning the White House Office of Science and Technology and prior biotech ventures including NeuroRx. CEO Stephen Willard oversees corporate operations and financing. Javitt's academic affiliation with Johns Hopkins informs the firm's clinical-trial design.
What is the firm's primary asset, and where does it stand with the FDA?
NRX-101, a fixed-dose oral combination of D-cycloserine and lurasidone, is the lead asset targeting suicidal bipolar depression. The FDA has granted it Qualified Infectious Disease Product and Fast Track designations. In July 2024, an independent monitoring board recommended its Phase 2b/3 trial proceed without changes, a signal the study did not require early termination for futility or safety.
How did NRX Pharmaceuticals access public markets?
NRX was formed through the May 2021 merger of NeuroRx, a private biotech, with Big Rock Partners Acquisition Corp., a publicly traded special purpose acquisition company. The SPAC deal gave the combined entity an equity valuation near $500 million and a Nasdaq listing under the ticker NRXP, typical of the 2020–2021 biotech listing wave.
Is NRX Pharmaceuticals a family office or a drug-development company?
It is a publicly traded clinical-stage pharmaceutical company, not a family office. The firm deploys its balance sheet — funded through equity raises — entirely toward advancing its own drug pipeline. It does not invest in external funds, co-invest alongside other allocators, or manage third-party capital.
Does NRX have any ownership stake in ketamine manufacturing or supply chain?
NRX does not own manufacturing assets. It has an exclusive supply-chain agreement with Nephron Pharmaceuticals for production of its ketamine-based formulations. The firm's intravenous ketamine, NRX-100, relies on this contract, while clinical supplies for NRX-101 are sourced through standard pharmaceutical manufacturing partnerships.
What happens if the Phase 2b/3 trial fails?
NRX is effectively a single-asset company. The failure of NRX-101 in its pivotal trial would likely force a restructuring, asset sale, or cessation of operations. The firm's pipeline beyond NRX-101 — a COVID-related asset and NRX-100 — remains early and unfunded for late-stage trials, making the lead program binary for the current corporate structure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: